Patients with chronic lymphocytic leukemia have a long course of the disease, ranging from the possibility of a lifetime without treatment to the time when the disease progresses to a rapid short-term progression that varies from person to person.
Chronic lymphocytic leukemia is an inert neoplasm originating from mature B lymphocytes, and pathologically manifests as a large number of monoclonal B lymphocytes in lymphoid tissues, including bone marrow, lymph nodes, peripheral blood, and spleen.
Previous treatment was mostly palliative, with the main purpose of reducing tumor load and improving symptoms. In recent years, chemotherapy combined with monoclonal antibodies has greatly improved the therapeutic response rate as well as the survival rate of patients, and the drugs include ibrutinib, etc. Patients with low prognostic risk can even achieve lifelong progression-free with standardized treatment.
Specific disease diagnosis and treatment should be carried out under the guidance of physicians.